Her2-positive breast cancer patients have shown significant improvement in prognosis and clinical outcome with the incorporation of Her2-target agents such as trastuzumab (a monoclonal antibody) and lapatinib (a tyrosine kinase inhibitor) into the conventional therapy [5, 6]. The gene discussed is ERBB2; the disease is breast cancer.